{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.53","upperLimit":"8.31","value":"3.63"},{"groupId":"OG001","lowerLimit":"11.01","upperLimit":"11.01","value":"11.01"},{"groupId":"OG002","lowerLimit":"3.88","upperLimit":"3.88","value":"3.88"},{"groupId":"OG003","lowerLimit":"10.45","upperLimit":"10.45","value":"10.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"OS is defined as the time from the start of treatment until time of death from any cause, for up to 3 years after completion of therapy. OS will be reported using the Kaplan-Meier method, along with a 95% confidence interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ended treatment at the regular dose level: 80 intravenous (IV)/80 Intraperitoneal (IP) + 300 twice a day (BID).","id":"OG000","title":"Intravenous Paclitaxel Dose Level 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for Intraperitoneal (IP) Paclitaxel (80 IP) and by mouth (PO) nilotinib (300 twice a day (BID) but declined to go up to the 80mg/m\\^2 of intravenous (IV) Paclitaxel.","id":"OG001","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for intravenous (IV) and Intraperitoneal (IP) Paclitaxel (80 IV/80 IP) but had a dose reduction for Nilotinib (400 every day (QD).","id":"OG002","title":"Intravenous Paclitaxel DoseLevel 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level -1"},{"description":"Had the planned dose of Intraperitoneal (IP) Paclitaxel (80 IP) but had a dose reduction for intravenous (IV) Paclitaxel (60 IV), and a dose reduction for Nilotinib (400 every day (QD).","id":"OG003","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel DoseLevel 1, Nilotinib Dose Level -1"}],"paramType":"MEDIAN","populationDescription":"7/21 participants were analyzed because 12 participants were not treated and 2 refused further treatment.","reportingStatus":"POSTED","timeFrame":"Participants were followed from time of initiation of study treatment to death or last follow-up through study completion for 27 months, 14 days","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}